26 results
8-K
EX-99.2
LYEL
Lyell Immunopharma, Inc.
26 Jun 24
Regulation FD Disclosure
8:32am
-negative breast cancer American Cancer Society (cancer.org); Balakrishnan et al., Clin Cancer Res 2017; Liu et al., Sci Reports, 2020; 34 ©2024 Lyell
8-K
EX-99.1
LYEL
Lyell Immunopharma, Inc.
28 Feb 24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023
4:07pm
Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
LYL845 – A novel epigenetically reprogrammed TIL product candidate using Lyell’s … .
Presented posters highlighting preclinical development of LYL119 at the American Society for Gene and Cell Therapy (ASGCT) and at SITC
8-K
EX-99.1
ug0y4 4vfk
7 Nov 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023
4:08pm
8-K
EX-99.1
o8ourh7k
11 Sep 23
Regulation FD Disclosure
9:16am
8-K
EX-99.1
f6de9yck yhpj
8 Aug 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023
4:10pm
8-K
EX-99.1
42sxidb
4 May 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4:11pm
8-K
EX-99.1
4cmra5nv wi
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm
8-K
EX-99.1
36zgjupp rem
4 Aug 22
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
fot fwxwk
10 May 22
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
4:14pm
DEF 14A
993 obf7ds4s
28 Apr 22
Definitive proxy
4:11pm
8-K
EX-99.1
5zu13
12 Aug 21
Lyell Immunopharma Reports Second Quarter 2021 Financial Results and Business Highlights
4:18pm
424B4
ycod87 y6v8
18 Jun 21
Prospectus supplement with pricing info
12:00am